Long-term Safety of Sunitinib in Metastatic Renal Cell Carcinoma
- 1 February 2016
- journal article
- Published by Elsevier BV in European Urology
- Vol. 69 (2), 345-351
- https://doi.org/10.1016/j.eururo.2015.07.006
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Long-Term Response to Sunitinib Therapy for Metastatic Renal Cell CarcinomaClinical Genitourinary Cancer, 2013
- Pazopanib versus Sunitinib in Metastatic Renal-Cell CarcinomaNew England Journal of Medicine, 2013
- Thyroid dysfunction and tyrosine kinase inhibitors in renal cell carcinomaEndocrine-Related Cancer, 2013
- Skin toxicity and efficacy of sunitinib and sorafenib in metastatic renal cell carcinoma: a national registry-based studyAnnals of Oncology, 2012
- Targeted Therapies for Renal Cell Carcinoma: Review of Adverse Event Management StrategiesJNCI Journal of the National Cancer Institute, 2012
- Overall Survival and Updated Results from a Phase II Study of Sunitinib in Japanese Patients with Metastatic Renal Cell CarcinomaJapanese Journal of Clinical Oncology, 2010
- Phase II Study of Sunitinib Administered in a Continuous Once-Daily Dosing Regimen in Patients With Cytokine-Refractory Metastatic Renal Cell CarcinomaJournal of Clinical Oncology, 2009
- Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell CarcinomaJournal of Clinical Oncology, 2009
- Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysisAnnals of Oncology, 2009
- Cardiotoxicity associated with tyrosine kinase inhibitor sunitinibThe Lancet, 2007